Reuters logo
BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
2017年10月12日 / 晚上8点54分 / 10 天内

BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients

Oct 12 (Reuters) - Mirati Therapeutics Inc

* Mirati Therapeutics’ mocetinostat included in stand up to cancer’s cutting-edge clinical trial initiative for NSCLC patients Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below